You are currently viewing this release in search mode. The search phrase, therma bright, will be highlighted in yellow where it appears in the news release. You can exit search mode by clicking here.

Therma Bright & Orpheus Medica to be Featured on BTV Business Television on BNN Bloomberg

September 23, 2020 7:00 AM EDT | Source: Therma Bright Inc.

Toronto, Ontario--(Newsfile Corp. - September 23, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce they will be appearing on National TV on Saturday September 26 and Sunday September 27, 2020. The interview will focus on Therma's products and CoviSafeTM, a rapid test for detecting SARS-CoV-2 in saliva.

BTV-Business Television is Canada's longest running business show. With Hosts Taylor Thoen and Jessica Katrichak, BTV features emerging companies across the country to bring viewers investment opportunities. BTV-Business Television

THERMA BRIGHT on BTV BROADCAST NETWORKS and TIMES:
CANADA:

BNN Bloomberg - Saturday Sept 26 @ 8:00pm EST, Sunday Sept 27 @ 4:30pm EST
Bell Express Vu - Saturday Sept 26 @ 8:00pm EST, Sunday Sept 27 @ 4:30pm EST

US National:
Biz Television Network - Sun Oct 4 @ 5:30am, 6pm & 9:00pm PST, Tues Oct 6 @ 5:00pm & 8:00pm PST

About Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV (TSXV: THRM) (FSE: JNX). For more information visit: www.thermabright.com and www.coldsores.com

About Orpheus Medica Inc.

Orpheus Medica is a fully integrated research-driven Canadian biotech company focused on the development and commercialization of innovative diagnostic and therapeutics for unmet medical needs. Orpheus, with its fully integrated R&D infrastructure, provides strategic partners and collaborators access to its proven and proprietary discovery and development of novel biopharmaceutical products. Our team has over 15 years of proven and validated computational capabilities for analysis and optimization of single-domain antibodies and other polypeptides.

For further information, please contact:

Therma Bright
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter:

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/3127/64448_5e5cf7a3440f6bb4_001full.jpg

Orpheus Medica.
Saeid Babaei, Chairman & CEO
sbabaei@orpheusmed.com

FORWARD LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/3127/64448_5e5cf7a3440f6bb4_002full.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64448

info